8-K: Agilon Health Reports 39% Revenue Increase in Q2 2024, Maintains Full-Year Guidance

Agilon Health's second quarter results show a 39% revenue increase to $1.5 billion, alongside a 38% rise in Medicare Advantage membership, while maintaining its full-year medical margin and adjusted EBITDA guidance.

Summary

• Agilon Health reported a 39% increase in revenue to $1.48 billion for the second quarter of 2024, compared to $1.07 billion in the same period of 2023.
• Medicare Advantage membership grew by 38% to 513,000, and total members on the agilon platform increased by 40% to 645,000.
• The company experienced a net loss of $31 million in Q2 2024, compared to a $17 million loss in Q2 2023.
• Gross profit decreased to $32 million in Q2 2024 from $55 million in Q2 2023.
• Medical margin was $106 million in Q2 2024, down from $134 million in Q2 2023.
• Adjusted EBITDA showed a loss of $3 million in Q2 2024, compared to a profit of $12 million in Q2 2023.
• Agilon Health maintained its full-year 2024 guidance for medical margin between $400 million and $450 million and adjusted EBITDA between a loss of $60 million and a loss of $15 million.
• The company's action plan includes refining payor relationships, increasing PCP engagement, improving data visibility, and accelerating operating efficiency.
• A retroactive termination of select contracts reduced membership by 17,000 and revenue by $110 million, but had no impact on medical margin for the second quarter.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue and membership growth are positive, the decrease in profitability metrics and the net loss are concerning. The company is taking action to improve performance, but the overall sentiment is neutral to slightly negative due to the financial losses.

Positives

• Revenue increased significantly by 39% year-over-year.
• Medicare Advantage membership saw a substantial 38% increase.
• Total membership on the platform grew by 40%.
• The company is maintaining its full-year guidance for medical margin and adjusted EBITDA.
• Agilon is making progress on its action plan to improve performance.
• Platform support costs are trending below the target for 2024.
• The company has a strong cash position with $408 million in cash, cash equivalents, and marketable securities.

Negatives

• The company experienced a net loss of $31 million in the second quarter of 2024, which is worse than the $17 million loss in the same period of 2023.
• Gross profit decreased by 41% year-over-year.
• Medical margin decreased by 21% year-over-year.
• Adjusted EBITDA showed a loss of $3 million, compared to a profit of $12 million in the same period last year.
• A retroactive termination of select contracts reduced revenue by $110 million.

Risks

• The company has a history of net losses and expects expenses to increase.
• There is a risk of failure to identify and develop successful new geographies, physician partners, and payors.
• Medical expenses could exceed revenues.
• The company's ability to secure contracts with Medicare Advantage payors is a risk.
• There is a risk of a significant reduction in membership.
• The transition to a Total Care Model may be challenging for physician partners.
• Inaccuracies in estimates of risk adjustment factors and medical service expenses could impact results.
• The company relies on a limited number of key payors.
• There are risks associated with changes to federal government healthcare programs.
• The company is subject to federal and state investigations, audits, and enforcement actions.

Future Outlook

Agilon Health maintains its full-year 2024 guidance for medical margin between $400 million and $450 million and adjusted EBITDA between a loss of $60 million and a loss of $15 million. The company also provided guidance for the third quarter of 2024, including revenue between $1.465 billion and $1.475 billion, medical margin between $90 million and $110 million, and adjusted EBITDA between a loss of $30 million and a loss of $10 million.

Management Comments

• Our second quarter results were in-line with our guidance, and we are maintaining medical margin and Adjusted EBITDA guidance for the full year, said Steve Sell, chief executive officer.
• We continue to make progress implementing our performance action plan which should contribute to accelerating our profitability over time and strengthening our value proposition to physicians and payers.

Industry Context

This announcement comes as the healthcare industry continues to shift towards value-based care models. Agilon Health's focus on empowering physicians and transitioning to a Total Care Model aligns with this trend. The company's growth in Medicare Advantage membership reflects the increasing adoption of these plans. However, the challenges in achieving profitability and managing medical costs are common in this sector.

Comparison to Industry Standards

• Agilon's 39% revenue growth is strong compared to some of its peers in the healthcare services sector, such as Oak Street Health, which has also seen significant growth but faces similar profitability challenges.
• The 38% increase in Medicare Advantage membership is also notable, as many companies in this space are focused on expanding their reach in this market, such as Humana and UnitedHealth Group.
• However, the decrease in gross profit and medical margin, along with the adjusted EBITDA loss, indicates that Agilon is facing challenges in managing costs, which is a common issue for companies in the value-based care space. Companies like Cano Health have also struggled with profitability despite revenue growth.
• Agilon's focus on improving operating efficiency and refining payor relationships is a common strategy among companies in this sector, as they seek to balance growth with profitability.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased profitability metrics.
• Physician partners may benefit from the company's efforts to improve its value proposition.
• Payors may be impacted by the company's efforts to refine payor relationships.
• Employees may be affected by the company's focus on operating efficiency.

Next Steps

• Agilon Health will continue to implement its performance action plan.
• The company will focus on onboarding the remaining member data into its financial data pipeline.
• Agilon will continue to work on improving operating expense efficiency.
• The company will host a conference call to discuss the second quarter results.

Key Dates

Keywords

agilon health, Medicare Advantage, healthcare, revenue, membership, EBITDA, medical margin, physician partners, value-based care, financial results